Upadacitinib(Rinvoq)

Another NameRinvoq、LuciUpa

IndicationsFor the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged ≥2 years, and active psoriatic arthritis in patients aged 2 to <18 years with inadequate response or